Associated Papers
Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.
Usui Y et al.
Blood Cancer Discovery, 2025
40525786 (PubMed )
Supplement: bcd-24-0355_table_s2_suppst2.xlsx › Sheet1
MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience.
Dhiab RB et al.
Scientific Reports, 2025
40456875 (PubMed )
Supplement: 41598_2025_99541_MOESM2_ESM.xlsx › Feuil1
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP et al.
The Oncologist, 2021
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma.
Zengin ZB et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
34130999 (PubMed )
Supplement: 10780432ccr210572-sup-260633_2_supp_7138642_qtl5pw.xlsx › Supplementary_Table_1
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.
Yang F et al.
Nature Cancer, 2021
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
Lowder CY et al.
Surgical Oncology, 2020
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK et al.
Nature Communications, 2015
25855536 (PubMed )
Supplement: ncomms7744-s2.xlsx › MUTATIONS_ALL_CASES
Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ et al.
Biomed Research International, 2015
26351634 (PubMed )
Supplement: 478017.f1.zip › 478017.f1 › mat.478017.v1__1_.xlsx › Supp_Table_1
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
25164765 (PubMed )
Supplement: 13059_2014_454_MOESM1_ESM.xlsx › Sheet1
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L et al.
Breast Cancer Research : Bcr, 2012
22551440 (PubMed )
Supplement: bcr3179-S4.PDF
Select a paper to view details